2024
Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilagan-Ying Y, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan S, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. Surgical Oncology Insight 2024, 1: 100007. DOI: 10.1016/j.soi.2024.100007.Peer-Reviewed Original ResearchFactors associated with early mortalityCases of pancreatic adenocarcinomaPancreatic adenocarcinoma resectionRisk of early mortalityLength of stayEarly mortalityAdjuvant chemotherapyPancreatic adenocarcinomaChemotherapy utilizationAdenocarcinoma resectionRisk factors associated with early mortalityOmission of adjuvant therapyNon-metastatic pancreatic adenocarcinomaMultivariate Cox regression modelAssociated with early mortalityPost-resection survivalIncreased risk of early mortalityParticipant Use FileProlonged hospital stayProlonged length of stayAdjuvant chemotherapy utilizationDecrease perioperative complicationsCox regression modelsNon-academic centersHospital risk factors
2021
1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durhman J, Liden S, Miles T, Lopez-Vidal T, Leatherman J, Sharma A, Ahuja N, Weekes C, O'Dwyer P, Monga D, Binder K, Azad N. 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals Of Oncology 2021, 32: s1087-s1088. DOI: 10.1016/j.annonc.2021.08.797.Peer-Reviewed Original Research
2019
Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities
Baretti M, Ahuja N, Azad N. Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities. Annals Of Pancreatic Cancer 2019, 2: 18-18. DOI: 10.21037/apc.2019.10.01.Peer-Reviewed Original ResearchEpigenetic modulatory drugsEpigenetic alterationsGene expressionImmediate translational implicationsProgression of PAADEpigenetic regulationHeritable differencesEpigenetic abnormalitiesPrimary sequenceTumor microenvironmentNucleosomesEssential roleCurrent knowledgeTranslational applicationsComplex seriesDNATranslational implicationsNew therapeutic approachesExpressionPancreatic adenocarcinomaEpigenomeChromatinEpigeneticsSubsequent interactionAlterations
2017
Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker‐Prietz A, Chen L, Laheru DA, De Jesus‐Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang C, Zheng L. Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine 2017, 6: 1552-1562. PMID: 28639410, PMCID: PMC5504321, DOI: 10.1002/cam4.1104.Peer-Reviewed Original ResearchConceptsMedian overall survivalUpfront chemotherapyNeoadjuvant chemotherapyNeoadjuvant therapySurgical resectionOverall survivalUpfront chemoradiationBorderline resectable pancreatic adenocarcinomaLong-term survival benefitBorderline resectable pancreatic cancerCurative surgical resectionResectable pancreatic cancerUpfront neoadjuvant chemotherapyResectable pancreatic adenocarcinomaSubpopulation of patientsJohns Hopkins HospitalLong-term survivalCurative intentNeoadjuvant chemoradiationConsecutive patientsSurvival benefitPancreatic cancerPancreatic adenocarcinomaRetrospective analysisChemoradiation
2016
Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma
Poruk KE, Valero V, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals Of Surgery 2016, 264: 1073-1081. PMID: 26756760, PMCID: PMC4936958, DOI: 10.1097/sla.0000000000001600.Peer-Reviewed Original ResearchConceptsCytokeratin-positive CTCsPancreatic adenocarcinomaMesenchymal markersVimentin-positive CTCsEpithelial tumor cells (ISET) methodFourth leading causeBetter treatment stratificationPortal blood samplesSignificant independent predictorsPotential prognostic biomarkerBiology of metastasisDetection of CTCsSurgical resectionIndependent predictorsPrognostic factorsMedian timeMultivariable analysisPDAC patientsPrognostic utilityCancer deathPatient prognosisLeading causeTreatment stratificationCancer recurrencePoor survival
2015
Early detection of pancreatic cancer.
Kim VM, Ahuja N. Early detection of pancreatic cancer. Chinese Journal Of Cancer Research 2015, 27: 321-31. PMID: 26361402, PMCID: PMC4560741, DOI: 10.3978/j.issn.1000-9604.2015.07.03.Peer-Reviewed Original ResearchPancreatic cancerPancreatic adenocarcinomaRisk factorsEarly detectionFourth common causeNew cancer casesGenetic risk factorsCancer deathCancer mortalityDefinitive curePrecursor lesionsCancer casesCommon causeWidespread screeningRisk-based strategyCancerNoninvasive methodGenetic mutationsMortal diseaseAdenocarcinomaCurrent standardDiseaseBest chanceClear needCause
2014
Association of recurrence patterns following resection of pancreatic adenocarcinoma with overall survival.
He J, Rezaee N, Wu W, Cameron J, Ahuja N, Pawlik T, Herman J, Hruban R, Weiss M, Zheng L, Wolfgang C. Association of recurrence patterns following resection of pancreatic adenocarcinoma with overall survival. Journal Of Clinical Oncology 2014, 32: 4127-4127. DOI: 10.1200/jco.2014.32.15_suppl.4127.Peer-Reviewed Original Research
2013
Is It Necessary to Follow Patients after Resection of a Benign Pancreatic Intraductal Papillary Mucinous Neoplasm?
He J, Cameron JL, Ahuja N, Makary MA, Hirose K, Choti MA, Schulick RD, Hruban RH, Pawlik TM, Wolfgang CL. Is It Necessary to Follow Patients after Resection of a Benign Pancreatic Intraductal Papillary Mucinous Neoplasm? Journal Of The American College Of Surgeons 2013, 216: 657-665. PMID: 23395158, PMCID: PMC3963007, DOI: 10.1016/j.jamcollsurg.2012.12.026.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmNoninvasive intraductal papillary mucinous neoplasmsPapillary mucinous neoplasmPancreatic cancerFamily historyMucinous neoplasmsNegative marginsInitial operationPancreatic intraductal papillary mucinous neoplasmsPartial pancreatic resectionMetastatic pancreatic adenocarcinomaInvasive pancreatic cancerRisk of developmentDegree of dysplasiaInitial surgeryMargin statusPancreatic resectionClose surveillanceInvasive adenocarcinomaPancreatic adenocarcinomaResectionPatientsCancerSurgeryAdenocarcinoma
2010
Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas
Poultsides GA, Reddy S, Cameron JL, Hruban RH, Pawlik TM, Ahuja N, Jain A, Edil BH, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL. Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas. Annals Of Surgery 2010, 251: 470-476. PMID: 20142731, PMCID: PMC3437748, DOI: 10.1097/sla.0b013e3181cf8a19.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmPancreatic ductal adenocarcinomaResection of IPMNsAdverse pathologic characteristicsInvasive pancreatic adenocarcinomaAdvanced T stageLymph node metastasisInvasive adenocarcinomaPancreatic adenocarcinomaFavorable survivalNode metastasisPathologic characteristicsT stageVascular invasionRegional lymph node metastasisFavorable biologic behaviorMicroscopic margin involvementPancreatic resection databasePositive resection marginsCox regression analysisHigh tumor gradePapillary mucinous neoplasmPoor tumor differentiationCurative intentMargin involvement
2008
Retroperitoneal masses with associated human chorionic gonadotropin production: Report of two cases
Duffield AS, Jarrar P, Shum C, Ahuja N, Yeo CJ, Sokoll LJ. Retroperitoneal masses with associated human chorionic gonadotropin production: Report of two cases. Clinica Chimica Acta 2008, 395: 166-169. PMID: 18505680, DOI: 10.1016/j.cca.2008.04.030.Peer-Reviewed Original ResearchConceptsHuman chorionic gonadotropinSerum human chorionic gonadotropinSerum hCG concentrationsRetroperitoneal massHCG concentrationsEpidermoid cystHCG secretionHuman chorionic gonadotropin productionCancer antigen 19Course of diseaseChorionic gonadotropin productionBenign epidermoid cystPancreatic ductal adenocarcinomaPathologic examinationAntigen 19Gonadotropin productionCyst liningMalignant neoplasmsDisease progressionDuctal adenocarcinomaPancreatic adenocarcinomaImmunohistochemical stainingChorionic gonadotropinPatientsCysts